, Caihela Hushud2,‡
, Xianghui Bai1,‡
, Nagongbilige2
, Wuliji Che3,*
, Hongyun Wu4
, Jun Fang5
, Wenfeng Bao6
, Baojun De2
, Narengerile Tong6
, Bo Cui6
, Lina Yang6
, Yiligema Ge1
, Siqintonglaga Wang2
, Vrajesh Mehta7
, Qiong Hu7
, Yu Du7,*
1Psychosomatic Medicine Department, Inner Mongolia International Mongolian Hospital, Hohhot, China
2Mongolian Psychosomatic Medicine Department of Azitai Mongolian Medicine Hospital of Inner Mongolia, Erdos, China
3National Engineering Research Center for Engineering Plastics, Chinese Academy of Sciences, Beijing, China
4Foreign Languages School, Renmin University of China, Beijing, China
5Psychosomatic Medicine Department, Inner Mongolia Traditional Chinese & Mongolian Medical Research Institute, Hohhot, China
6Inner Mongolia Medical University, Hohhot, China
7Business Analytics Discipline, University of Colorado Denver, Denver, CO, USA
©2025 Jaseng Medical Foundation
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Author Contributions
Conceptualization: ND, CH, XB, and N. Methodology: WC and HW. Formal investigation: JF and WB. Data analysis: BD, NT, BC, LY, YG, and SW. Writing original draft: WC and YD. Writing - review and editing: ND, CH, XB, HW, NT, VM, QH, and YD.
Conflicts of Interest
There is no conflict of interest to declare.
Author Use of AI Tools Statement
During the preparation of this work the authors used generative AI tools to improve language and readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Funding
This study was supported by the Inner Mongolia Medical Research Foundation (grant no.: IMRF-2023-09).
Ethical Statement
This article did not include any personal information. General research ethics guidelines were followed.
| Authors (year) [reference] | Study design | Sample size | Condition | Key findings |
|---|---|---|---|---|
| Nagongbilige et al (2018) [6] | Retrospective cohort | 316 patients | Chronic insomnia | Significant improvement in Athens Insomnia Scale (AIS) scores post-treatment (15.05 → 4.30) and long-term (>10 months; 6.04) (both p < 0.001)Athen scores achieved 70.9% post-treatment (normal sleep status) |
| Chagan-Yasutan et al (2020) [7] | Pilot prospective | 21 patients | Esophageal cancer | Patients were evaluated the quality of life before and after MMBIT using the two questionnaires of EORTC QLQ-OES 18 and QLICP-OES. Statistical significant improvement on physical function (p < 0.0001), psychological function (p < 0.05), common symptoms, and side effects (p < 0.05), such as reflux. |
| Chagan-Yasutan et al (2024) [8] | Exosome proteomics | 15 samples (5 psoriasis patients pre/post-MMBIT, 5 HCs); Validation tests in serum samples of psoriasis (n = 56) and HC (n = 29) | Psoriasis | 75% improvement in Psoriasis Area Severity Index (PASI) after 60 days of MMBIT41 DEPs altered in psoriasis vs. healthy controls (HCs), implicating ribosome/apelin-APJ pathways. 16 DEPs significantly changed post-therapy, linked to recovery pathways: Fc gamma-mediated phagocytosis, tight junction repair, and vascular smooth muscle contraction. Immunoglobulins: One significantly reduced in psoriasis was elevated post-MMBIT. Elafin (validated in n = 85) : Higher in psoriasis vs. HCs (p < 0.0001) but significantly decreased post-MMBIT (p < 0.01). |
| Fang et al (2024) [9] | Multi-omics mechanistic | 20 patients: 10 with MMBIT (NDT); 10 with MMBIT and oral dipine antihypertensive drugs (DT) | Essential hypertension | MMBIT reduces SBP in patients with essential hypertension, potentially through the interaction of 5-HT and 5-HTR2B, facilitating nitric oxide (NO)-mediated vasodilation.Post-MMBIT, 5-HT levels rose significantly in the NDT group but not in the DT group (p < 0.05).Molecular Effects: MMBIT modulates key expressed genes DEGs (e.g., 5-HTR2B) and alters protein expressions like S100A2 (p < 0.05).MMBIT reduces NO while increasing malondialdehyde and NO synthetase levels (p < 0.05). |
AIS = Athens insomnia scale; APJ = apelin receptor; DEPs = differentially expressed proteins; DEGs = differentially expressed genes; DT = treat with antihypertensive drugs; EORTC QLQ-OES 18 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Oesophageal Cancer 18; HCs = healthy controls; HT = hydroxytryptamine; HTR2B = 5-hydroxytryptamine receptor 2B; NDT = treat without antihypertensive drugs; NO = nitric oxide; PASI = psoriasis area and severity index; QLICP-OES = Quality of Life Instrument for Cancer Patients-Oesophageal Cancer; SBP = systolic blood pressure; S100A2 = S100 calcium-binding protein A2.
| Authors (year) [reference] | Study design | Sample size | Condition | Key findings |
|---|---|---|---|---|
| Nagongbilige et al (2018) [ |
Retrospective cohort | 316 patients | Chronic insomnia | Significant improvement in Athens Insomnia Scale (AIS) scores post-treatment (15.05 → 4.30) and long-term (>10 months; 6.04) (both p < 0.001)Athen scores achieved 70.9% post-treatment (normal sleep status) |
| Chagan-Yasutan et al (2020) [ |
Pilot prospective | 21 patients | Esophageal cancer | Patients were evaluated the quality of life before and after MMBIT using the two questionnaires of EORTC QLQ-OES 18 and QLICP-OES. Statistical significant improvement on physical function (p < 0.0001), psychological function (p < 0.05), common symptoms, and side effects (p < 0.05), such as reflux. |
| Chagan-Yasutan et al (2024) [ |
Exosome proteomics | 15 samples (5 psoriasis patients pre/post-MMBIT, 5 HCs); Validation tests in serum samples of psoriasis (n = 56) and HC (n = 29) | Psoriasis | 75% improvement in Psoriasis Area Severity Index (PASI) after 60 days of MMBIT41 DEPs altered in psoriasis vs. healthy controls (HCs), implicating ribosome/apelin-APJ pathways. 16 DEPs significantly changed post-therapy, linked to recovery pathways: Fc gamma-mediated phagocytosis, tight junction repair, and vascular smooth muscle contraction. Immunoglobulins: One significantly reduced in psoriasis was elevated post-MMBIT. Elafin (validated in n = 85) : Higher in psoriasis vs. HCs (p < 0.0001) but significantly decreased post-MMBIT (p < 0.01). |
| Fang et al (2024) [ |
Multi-omics mechanistic | 20 patients: 10 with MMBIT (NDT); 10 with MMBIT and oral dipine antihypertensive drugs (DT) | Essential hypertension | MMBIT reduces SBP in patients with essential hypertension, potentially through the interaction of 5-HT and 5-HTR2B, facilitating nitric oxide (NO)-mediated vasodilation.Post-MMBIT, 5-HT levels rose significantly in the NDT group but not in the DT group (p < 0.05).Molecular Effects: MMBIT modulates key expressed genes DEGs (e.g., 5-HTR2B) and alters protein expressions like S100A2 (p < 0.05).MMBIT reduces NO while increasing malondialdehyde and NO synthetase levels (p < 0.05). |
AIS = Athens insomnia scale; APJ = apelin receptor; DEPs = differentially expressed proteins; DEGs = differentially expressed genes; DT = treat with antihypertensive drugs; EORTC QLQ-OES 18 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Oesophageal Cancer 18; HCs = healthy controls; HT = hydroxytryptamine; HTR2B = 5-hydroxytryptamine receptor 2B; NDT = treat without antihypertensive drugs; NO = nitric oxide; PASI = psoriasis area and severity index; QLICP-OES = Quality of Life Instrument for Cancer Patients-Oesophageal Cancer; SBP = systolic blood pressure; S100A2 = S100 calcium-binding protein A2.